By IDSE News Staff
MADRID—Relebactam, an investigational beta-lactamase inhibitor, used with imipenem-cilastatin was efficacious against carbapenem-resistant Enterobacteriaceae, according to phase 3 data presented at the 2018 European Congress of Clinical Microbiology and Infectious Diseases.
Imipenem-cilastatin combined with relebactam (IMI/REL, Merck) was also well tolerated, according to Amanda Paschke, MD, the senior principal scientist of infectious disease clinical research